• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    5/17/24 1:35:23 PM ET
    $ARDX
    $BPMC
    $CYTK
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDX alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    MRK CALL SWEEP BEARISH 05/24/24 $133.00 $28.5K 477 2.1K
    INSM CALL SWEEP BULLISH 07/19/24 $45.00 $34.5K 20.0K 978
    MRNA CALL SWEEP BEARISH 06/21/24 $130.00 $121.4K 4.0K 389
    IQV CALL SWEEP BEARISH 06/21/24 $240.00 $32.3K 661 310
    BPMC CALL TRADE BULLISH 06/21/24 $110.00 $47.8K 62 228
    ARDX PUT SWEEP BULLISH 10/18/24 $10.00 $28.3K 1.1K 174
    VKTX CALL SWEEP BEARISH 07/19/24 $95.00 $64.0K 1.2K 172
    CYTK PUT SWEEP BEARISH 05/24/24 $60.00 $27.4K 19 135
    NVO CALL TRADE BEARISH 01/17/25 $100.00 $374.5K 1.7K 113
    TDOC CALL SWEEP NEUTRAL 05/17/24 $12.00 $33.7K 922 110

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For MRK (NYSE:MRK), we notice a call option sweep that happens to be bearish, expiring in 7 day(s) on May 24, 2024. This event was a transfer of 1018 contract(s) at a $133.00 strike. This particular call needed to be split into 54 different trades to become filled. The total cost received by the writing party (or parties) was $28.5K, with a price of $28.0 per contract. There were 477 open contracts at this strike prior to today, and today 2119 contract(s) were bought and sold.

    • For INSM (NASDAQ:INSM), we notice a call option sweep that happens to be bullish, expiring in 63 day(s) on July 19, 2024. This event was a transfer of 69 contract(s) at a $45.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.5K, with a price of $500.0 per contract. There were 20051 open contracts at this strike prior to today, and today 978 contract(s) were bought and sold.

    • Regarding MRNA (NASDAQ:MRNA), we observe a call option sweep with bearish sentiment. It expires in 35 day(s) on June 21, 2024. Parties traded 130 contract(s) at a $130.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $121.4K, with a price of $935.0 per contract. There were 4006 open contracts at this strike prior to today, and today 389 contract(s) were bought and sold.

    • Regarding IQV (NYSE:IQV), we observe a call option sweep with bearish sentiment. It expires in 35 day(s) on June 21, 2024. Parties traded 100 contract(s) at a $240.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $32.3K, with a price of $323.0 per contract. There were 661 open contracts at this strike prior to today, and today 310 contract(s) were bought and sold.

    • Regarding BPMC (NASDAQ:BPMC), we observe a call option trade with bullish sentiment. It expires in 35 day(s) on June 21, 2024. Parties traded 114 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $47.8K, with a price of $420.0 per contract. There were 62 open contracts at this strike prior to today, and today 228 contract(s) were bought and sold.

    • Regarding ARDX (NASDAQ:ARDX), we observe a put option sweep with bullish sentiment. It expires in 154 day(s) on October 18, 2024. Parties traded 107 contract(s) at a $10.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $265.0 per contract. There were 1133 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold.

    • For VKTX (NASDAQ:VKTX), we notice a call option sweep that happens to be bearish, expiring in 63 day(s) on July 19, 2024. This event was a transfer of 153 contract(s) at a $95.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $64.0K, with a price of $420.0 per contract. There were 1225 open contracts at this strike prior to today, and today 172 contract(s) were bought and sold.

    • Regarding CYTK (NASDAQ:CYTK), we observe a put option sweep with bearish sentiment. It expires in 7 day(s) on May 24, 2024. Parties traded 123 contract(s) at a $60.00 strike. This particular put needed to be split into 66 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $220.0 per contract. There were 19 open contracts at this strike prior to today, and today 135 contract(s) were bought and sold.

    • For NVO (NYSE:NVO), we notice a call option trade that happens to be bearish, expiring in 245 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $374.5K, with a price of $3745.0 per contract. There were 1745 open contracts at this strike prior to today, and today 113 contract(s) were bought and sold.

    • For TDOC (NYSE:TDOC), we notice a call option sweep that happens to be neutral, is expiring today. Parties traded 450 contract(s) at a $12.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $33.7K, with a price of $75.0 per contract. There were 922 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDX
    $BPMC
    $CYTK
    $INSM

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Novo Nordisk A/S
    $NVO
    2/12/2026Underperform → Hold
    Jefferies
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Insmed Incorporated
    $INSM
    1/28/2026$231.00Overweight
    Barclays
    Cytokinetics Incorporated
    $CYTK
    1/28/2026$87.00Overweight
    Barclays
    Novo Nordisk A/S
    $NVO
    1/27/2026Neutral
    Citigroup
    Insmed Incorporated
    $INSM
    1/23/2026$212.00Buy
    Roth Capital
    More analyst ratings

    $ARDX
    $BPMC
    $CYTK
    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year

    2/19/26 4:01:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

    —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million——Total Company Revenues of $606.4 Million for Full-Year 2025——BRINSUPRI Total Revenues of $144.6 Million for Fourth-Quarter and $172.7 Million for Full-Year 2025——ARIKAYCE Total Revenues of $119.2 Million for Fourth-Quarter and $433.8 Million for Full-Year 2025, Representing 19% Annual Growth and Exceeding the Upper End of Full-Year 2025 Guidance——Topline Data Readouts from Phase 3 ENCORE and Phase 2b CEDAR Studies Remain on Track——FDA grants Orphan Drug Designation to Trepro

    2/19/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

    Second season results from the Phase 3 SMART trial were presented at the 9th RSVVW Conference and will be shared with the U.S. FDA and other regulatory authorities Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the safety, efficacy and pharmacokinetics of ENFLONSIA™ (clesrovimab) in infants and children at increased risk for severe respiratory syncytial virus (RSV) disease over two RSV seasons. The data were presented during an oral session (Abstract #P455) at RSVVW'26, the 9th conference of the Respiratory Syncytial Virus Foundation (ReSViNET) i

    2/19/26 5:15:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BPMC
    $CYTK
    $INSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Paulus Kenneth H bought $69,400 worth of shares (10,000 units at $6.94) (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    11/17/25 4:05:05 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Director Mott David M bought $725,880 worth of shares (200,000 units at $3.63), increasing direct ownership by 7% to 2,896,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/18/25 9:28:07 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $737,260 worth of shares (200,000 units at $3.69), increasing direct ownership by 8% to 2,696,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/11/25 9:40:28 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BPMC
    $CYTK
    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

    3/8/24 2:00:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BPMC
    $CYTK
    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00

    2/13/26 8:35:09 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S upgraded by Jefferies

    Jefferies upgraded Novo Nordisk A/S from Underperform to Hold

    2/12/26 7:19:33 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BPMC
    $CYTK
    $INSM
    SEC Filings

    View All

    SEC Form 144 filed by Ardelyx Inc.

    144 - ARDELYX, INC. (0001437402) (Subject)

    2/20/26 6:07:59 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Ardelyx Inc.

    144 - ARDELYX, INC. (0001437402) (Subject)

    2/20/26 5:33:56 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Moderna Inc.

    S-8 - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:03:07 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARDX
    $BPMC
    $CYTK
    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Smith Michael S

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    2/19/26 4:05:52 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Smith Michael S

    3 - Teladoc Health, Inc. (0001477449) (Issuer)

    2/19/26 4:05:23 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Officer Haas Bernd covered exercise/tax liability with 20 shares, decreasing direct ownership by 0.08% to 24,394 units (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    2/17/26 5:01:48 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ARDX
    $BPMC
    $CYTK
    $INSM
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

    Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.

    1/7/26 7:00:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ARDX
    $BPMC
    $CYTK
    $INSM
    Financials

    Live finance-specific insights

    View All

    Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year

    2/19/26 4:01:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

    —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million——Total Company Revenues of $606.4 Million for Full-Year 2025——BRINSUPRI Total Revenues of $144.6 Million for Fourth-Quarter and $172.7 Million for Full-Year 2025——ARIKAYCE Total Revenues of $119.2 Million for Fourth-Quarter and $433.8 Million for Full-Year 2025, Representing 19% Annual Growth and Exceeding the Upper End of Full-Year 2025 Guidance——Topline Data Readouts from Phase 3 ENCORE and Phase 2b CEDAR Studies Remain on Track——FDA grants Orphan Drug Designation to Trepro

    2/19/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors

    NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Michael Smith to its board of directors. With more than three decades of leadership experience in financial management and strategic transformation, Mr. Smith brings a deep understanding of long-term business sustainability within highly regulated, global markets. He joins the board following the previously announced retirements of Eric Evans and Thomas McKinley and will serve on the board's audit and nominating and corporate governance committees. "Michael's experience leading enterprise transformations makes him a strong addition to the Board," sa

    2/18/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $ARDX
    $BPMC
    $CYTK
    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    11/14/24 4:08:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cytokinetics Incorporated

    SC 13G - CYTOKINETICS INC (0001061983) (Subject)

    11/14/24 1:28:31 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care